Configuring therapeutic aspects of immune checkpoints in lung cancer

[thumbnail of cancers-15-00543.pdf]
cancers-15-00543.pdf - Published Version (1MB) | Preview
Available under license: Creative Commons Attribution

Khadela, Avinash ORCID: 0000-0001-9914-8539, Chavda, Vivek P ORCID: 0000-0002-7701-8597, Postwala, Humzah, Ephraim, Ramya, Apostolopoulos, Vasso ORCID: 0000-0001-6788-2771 and Shah, Yesha (2023) Configuring therapeutic aspects of immune checkpoints in lung cancer. Cancers, 15 (2). ISSN 2072-6694


Immune checkpoints are unique components of the body’s defense mechanism that safeguard the body from immune responses that are potent enough to harm healthy body cells. When proteins present on the surface of T cells recognize and bind to the proteins present on other tumor cells, immune checkpoints are triggered. These proteins are called immunological checkpoints. The T cells receive an on/off signal when the checkpoints interact with companion proteins. This might avert the host’s immune system from eliminating cancer cells. The standard care plan for the treatment of non-small cell lung cancer (NSCLC) has been revolutionized with the use of drugs targeting immune checkpoints, in particular programmed cell death protein 1. These drugs are now extended for their potential to manage SCLC. However, it is acknowledged that these drugs have specific immune related adverse effects. Herein, we discuss the use of immune checkpoint inhibitors in patients with NSCLC and SCLC, their outcomes, and future perspectives.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.3390/cancers15020543
Official URL
Subjects Current > FOR (2020) Classification > 3204 Immunology
Current > Division/Research > Australian Institute of Musculoskeletal Science (AIMSS)
Current > Division/Research > Institute for Health and Sport
Keywords cancer, cancer treatment, immunology, lung cancer, immune checkpoints
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login